FRE whats next, page-2

the share price will be what the share price will be. It might double based on the upcoming results at the end of july, it might double for 'no reason' at all months later or it might go down after the results. some people can pick the market, but knowing if it will go lower than 17c if delays with tga or double in price for approval is pretty hard if not impossible to determine with confidence.

if you think the product will be approved and will sell, then holding without worrying about fluctuations until that point is worth considering at least.

first hurdle is clinical results, which depending on results may see a nice bump.